133 related articles for article (PubMed ID: 38380966)
21. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
[TBL] [Abstract][Full Text] [Related]
22. [Distribution and Clinical Significance of CTLA-4, PD-1 and PD-L1 in Peripheral Blood of Patients with Small Cell Lung Cancer].
Li H; Liu Y; Liu Y; Liu J; Zhao D; Wang Y; Cheng Y
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):755-760. PubMed ID: 29167005
[TBL] [Abstract][Full Text] [Related]
23. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M
Mount CW; Majzner RG; Sundaresh S; Arnold EP; Kadapakkam M; Haile S; Labanieh L; Hulleman E; Woo PJ; Rietberg SP; Vogel H; Monje M; Mackall CL
Nat Med; 2018 May; 24(5):572-579. PubMed ID: 29662203
[TBL] [Abstract][Full Text] [Related]
24. Analysis of GD2/GM2 synthase mRNA as a biomarker for small cell lung cancer.
Chen LC; Brown AB; Cheung IY; Cheung NK; Kris MG; Krug LM
Lung Cancer; 2010 Feb; 67(2):216-20. PubMed ID: 19457569
[TBL] [Abstract][Full Text] [Related]
25. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.
Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC
Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536
[TBL] [Abstract][Full Text] [Related]
26. Co-Expression of an IL-15 Superagonist Facilitates Self-Enrichment of GD
Bodden M; Häcker A; Röder J; Kiefer A; Zhang C; Bhatti A; Pfeifer Serrahima J; Ullrich E; Kühnel I; Wels WS
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686586
[TBL] [Abstract][Full Text] [Related]
27. Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas.
Long AH; Highfill SL; Cui Y; Smith JP; Walker AJ; Ramakrishna S; El-Etriby R; Galli S; Tsokos MG; Orentas RJ; Mackall CL
Cancer Immunol Res; 2016 Oct; 4(10):869-880. PubMed ID: 27549124
[TBL] [Abstract][Full Text] [Related]
28. Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC.
Sen T; Della Corte CM; Milutinovic S; Cardnell RJ; Diao L; Ramkumar K; Gay CM; Stewart CA; Fan Y; Shen L; Hansen RJ; Strouse B; Hedrick MP; Hassig CA; Heymach JV; Wang J; Byers LA
J Thorac Oncol; 2019 Dec; 14(12):2152-2163. PubMed ID: 31470128
[TBL] [Abstract][Full Text] [Related]
29. Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer.
Taromi S; Firat E; Simonis A; Braun LM; Apostolova P; Elze M; Passlick B; Schumacher A; Lagies S; Frey A; Schmitt-Graeff A; Burger M; Schmittlutz K; Follo M; von Elverfeldt D; Zhu X; Kammerer B; Diederichs S; Duyster J; Manz MG; Niedermann G; Zeiser R
Cancer Lett; 2022 Jul; 538():215697. PubMed ID: 35487310
[TBL] [Abstract][Full Text] [Related]
30. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
Yuan X; Sun Z; Yuan Q; Hou W; Liang Q; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2021 Feb; 39(1):34-51. PubMed ID: 32772342
[TBL] [Abstract][Full Text] [Related]
31. Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas.
Zuo P; Li Y; He C; Wang T; Zheng X; Liu H; Wu Z; Zhang J; Liao X; Zhang L
Front Immunol; 2023; 14():1145706. PubMed ID: 37251413
[TBL] [Abstract][Full Text] [Related]
32. CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo.
Liu M; Huang W; Guo Y; Zhou Y; Zhi C; Chen J; Li J; He J; Lian H; Zhou J; Ye X; Hu Y; Hu H; Liu Z; Huang J; Lin L; Cai M; Wang X; Huang J; Zhang Z; Zhu K; Zhao Q; Cao B
J Leukoc Biol; 2022 Oct; 112(4):901-911. PubMed ID: 35088475
[TBL] [Abstract][Full Text] [Related]
33. Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products.
Sadeqi Nezhad M; Abdollahpour-Alitappeh M; Rezaei B; Yazdanifar M; Seifalian AM
Pharm Res; 2021 Jun; 38(6):931-945. PubMed ID: 34114161
[TBL] [Abstract][Full Text] [Related]
34. GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma.
Gargett T; Ebert LM; Truong NTH; Kollis PM; Sedivakova K; Yu W; Yeo ECF; Wittwer NL; Gliddon BL; Tea MN; Ormsby R; Poonnoose S; Nowicki J; Vittorio O; Ziegler DS; Pitson SM; Brown MP
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36167468
[TBL] [Abstract][Full Text] [Related]
35. iPSC-derived hypoimmunogenic tissue resident memory T cells mediate robust anti-tumor activity against cervical cancer.
Furukawa Y; Ishii M; Ando J; Ikeda K; Igarashi KJ; Kinoshita S; Azusawa Y; Toyota T; Honda T; Nakanishi M; Ohshima K; Masuda A; Yoshida E; Kitade M; Porteus M; Terao Y; Nakauchi H; Ando M
Cell Rep Med; 2023 Dec; 4(12):101327. PubMed ID: 38091985
[TBL] [Abstract][Full Text] [Related]
36. iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy.
Cichocki F; Bjordahl R; Gaidarova S; Mahmood S; Abujarour R; Wang H; Tuininga K; Felices M; Davis ZB; Bendzick L; Clarke R; Stokely L; Rogers P; Ge M; Robinson M; Rezner B; Robbins DL; Lee TT; Kaufman DS; Blazar BR; Valamehr B; Miller JS
Sci Transl Med; 2020 Nov; 12(568):. PubMed ID: 33148626
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma.
Tomida A; Yagyu S; Nakamura K; Kubo H; Yamashima K; Nakazawa Y; Hosoi H; Iehara T
Cancer Sci; 2021 Oct; 112(10):4026-4036. PubMed ID: 34382720
[TBL] [Abstract][Full Text] [Related]
38. Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant.
de Billy E; Pellegrino M; Orlando D; Pericoli G; Ferretti R; Businaro P; Ajmone-Cat MA; Rossi S; Petrilli LL; Maestro N; Diomedi-Camassei F; Pezzullo M; De Stefanis C; Bencivenga P; Palma A; Rota R; Del Bufalo F; Massimi L; Weber G; Jones C; Carai A; Caruso S; De Angelis B; Caruana I; Quintarelli C; Mastronuzzi A; Locatelli F; Vinci M
Neuro Oncol; 2022 Jul; 24(7):1150-1163. PubMed ID: 34964902
[TBL] [Abstract][Full Text] [Related]
39. 'Off-the-shelf' immunotherapy with iPSC-derived rejuvenated cytotoxic T lymphocytes.
Ando M; Nakauchi H
Exp Hematol; 2017 Mar; 47():2-12. PubMed ID: 27826124
[TBL] [Abstract][Full Text] [Related]
40. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
